Table 3—

Mean percent difference of biochemical markers of bone turnover between ALN and placebo groups among women with and without type 2 diabetes at 1 year

Diabetic women
Nondiabetic women
P value, test for homogeneity*
ALNPlaceboALNPlacebo
BSAP (units/l)
n1431392,9272,918
 Percent change from baseline−29.7 ± 1.9−7.6 ± 2.3§−31.2 ± 0.4−8.5 ± 0.4§
 Percent difference−22.1 (−27.5 to −16.7)−22.7 (−23.9 to −21.5)0.9
NTx (μg/l)
n1361262,6382,659
 Percent change from baseline−42.8 ± 2.6−10.9 ± 3.2§−51.3 ± 0.7−9.5 ± 0.7§
 Percent difference−31.9 (−40.9 to −23.0)−41.8 (−43.6 to −39.9)0.1
CTx (pmol/l)
n1411382,9182,907
 Percent change from baseline−52.4 ± 2.6−22.9 ± 4.0§−59.6 ± 0.6−31.0 ± 0.7§
 Percent difference−29.6 (−38.9 to −20.2)−28.6 (−30.4 to −26.8)0.2
  • Data are n, means ± SE, or means (95% CI).

  • *

    * P value for interaction between treatment and history of diabetes among all women combined;

  • P ≤ 0.001 vs. placebo;

  • P ≤ 0.001 vs. baseline;

  • §

    § P ≤ 0.05 vs. baseline;

  • mean percent difference between alendronate and placebo groups.